We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for casirivimab and imdevimab (Roche Products Pty Limited)
Active ingredients
casirivimab and imdevimab
Sponsor
Date of review outcome
Lapse date
Type
Provisional approval
Indication
For treatment of confirmed COVID-19 in patients aged 12 years and older and weighing at least 40 kg that do not require supplemental oxygen and who are at high risk of progressing to severe COVID-19.
For the prevention of COVID-19 in individuals aged 12 years and older and weighing at least 40 kg who meet one or more of the following criteria:
have been exposed or are at high risk of exposure to SARS-CoV-2
have a medical condition making them unlikely to respond to or be protected by vaccination
For the prevention of COVID-19 in individuals aged 12 years and older and weighing at least 40 kg who meet one or more of the following criteria:
have been exposed or are at high risk of exposure to SARS-CoV-2
have a medical condition making them unlikely to respond to or be protected by vaccination
Therapeutic area
Infectious diseases